Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Targeted covalent inhibition is an established approach for increasing the potency and selectivity of potential drug candidates, as well as identifying potent and selective tool compounds for target validation studies. It is evident that identification of reversible recognition elements is essential for selective covalent inhibition, but this must also be achieved with the appropriate level of inherent reactivity of the reactive functionality (or “warhead”). Structural changes that increase or decrease warhead reactivity, guided by methods to predict the effect of those changes, have the potential to tune warhead reactivity and negate issues related to potency and/or toxicity. The half-life to adduct formation with glutathione (GSH t 1/2 ) is a useful assay for measuring the reactivity of cysteine-targeting covalent warheads but is limited to synthesized molecules. In this manuscript we assess the ability of several experimental and computational approaches to predict GSH t 1/2 for a range of cysteine targeting warheads, including a novel method based on p K a . Furthermore, matched molecular pairs analysis has been performed against our internal compound collection, revealing structure–activity relationships between a selection of different covalent warheads. These observations and methods of prediction will be valuable in the design of new covalent inhibitors with desired levels of reactivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In some cases, covalent inhibitors can be designed to be cleared rapidly after blocking the PPI, which could reduce non-mechanism-based toxicity [37, 139].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [139]
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Bochevarov, A. D., Harder, E., Hughes, T. F., Greenwood, J. R., Braden, D. A., Philipp, D. M., Rinaldo, D., Halls, M. D., Zhang, J., & Friesner, R. A. (2013) · International Journal of Quantum Chemistry · doi:10.1002/qua.24481 · Cited by 1,798
Cysteine Proteases and Their Inhibitors
Otto, H.-H., & Schirmeister, T. (1997) · Chemical Reviews · doi:10.1021/cr950025u · Cited by 759
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Research works printed but not linked: 5
- 2017, Schrödinger Release 2017-2
- 2017, Schrödinger Release 2017-2: Ligprep
- Frisch M. J., 2009, Gaussian 09, Revision E.09
- 2017, Schrödinger Release 2017-2: Macromodel
- 2017, Jaguar, Version 9.5
Cited by
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles
Eaton, J. K., Furst, L., Ruberto, R. A., Moosmayer, D., Hilpmann, A., Ryan, M. J., Zimmermann, K., Cai, L. L., Niehues, M., Badock, V., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0501-5 · Cited by 489
Structure-based design of targeted covalent inhibitors
Lonsdale, R., & Ward, R. A. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00220c · Cited by 344
Self-citationAdvances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 317
Next generation 3D pharmacophore modeling
Schaller, D., Šribar, D., Noonan, T., Deng, L., Nguyen, T. N., Pach, S., Machalz, D., Bermudez, M., & Wolber, G. (2020) · WIREs Computational Molecular Science · doi:10.1002/wcms.1468 · Cited by 269
Metadata
- Authors
- Lonsdale, R., Burgess, J., Colclough, N., Davies, N. L., Lenz, E. M., Orton, A. L., & Ward, R. A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Ward, Richard A.
- Venue
- Journal of Chemical Information and Modeling
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-11-21
- Volume
- 57
- Issue
- 12
- Pages
- 3124-3137
- ISSN
- 1549-9596 (ISSN-L)
- 1549-960X
- OpenAlex
- W2769901316
- Cited by
- 190
- References
- 28
- Citations by year
- 2026: 20 · 2025: 27 · 2024: 25 · 2023: 28 · 2022: 22 · 2021: 20 · 2020: 23 · 2019: 18 · 2018: 7
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Chemical Information and Modeling (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- covalent warheads, matched molecular pairs, structure-activity relationship, covalent inhibitors
- MeSH terms
- Acrylamides, Cysteine, Glutathione, Humans, Models, Molecular, Structure-Activity Relationship, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity. https://app.cochat.ai/papers/10.1021/acs.jcim.7b00553
- The paper
- Lonsdale, R., Burgess, J., Colclough, N., Davies, N. L., Lenz, E. M., Orton, A. L., & Ward, R. A. (2017). Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity. Journal of Chemical Information and Modeling. https://doi.org/10.1021/acs.jcim.7b00553
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.